Adversarial Injection · Thiotepa (TESPA; CAS 52-24-4) NIOSH HD Category 1 / IARC Group 1 / OSHA No PEL / ACGIH No TLV / TEPA (CAS 545-55-1) Active Alkylating Metabolite EHS Monitoring Gap / Intravesical Bladder Instillation Urology Clinic Route Gap / TBF Pediatric HSCT Conditioning Three-HD Null Chain (Thiotepa + Busulfan [#445] + Fludarabine [#449]) · Attack #458

Thiotepa (TESPA; N,N',N''-triethylenethiophosphoramide; CAS 52-24-4; MW 189.22 g/mol; molecular formula C6H12N3PS; triaziridinyl phosphine sulfide alkylating agent; Wyeth/Lederle originator; Tepadina brand [ADIENNE]; Mechanism: thiotepa spontaneously ring-opens aziridine rings at physiologic pH → reactive ethylenimine intermediate → bifunctional DNA alkylation at N7-guanine and N3-adenine; CYP3A4/3A5 desulfuration in liver: thiotepa → TEPA [triethylenephosphoramide; CAS 545-55-1; MW 173.21 g/mol; active alkylating phosphoramide; also cytotoxic; t½ TEPA ~5 days vs thiotepa ~2 hours; TEPA accumulates to higher plasma concentrations than thiotepa after single dose; IARC Monograph 9 [1975] lists TEPA separately as Group 2B probable carcinogen; NIOSH Ca designation for TEPA CAS 545-55-1; EHS platforms hold independent TEPA CAS 545-55-1 record unlinked to thiotepa CAS 52-24-4]; OSHA: No PEL [CAS 52-24-4 absent from 29 CFR 1910.1000 Z-1 and Z-2 Tables]; ACGIH: No TLV-TWA; NIOSH: No REL — NIOSH Hazardous Drug Category 1 [2016 HD List]; IARC Monograph 50 [1990]: established human carcinogen (Group 1) — ovarian cancer, urothelial cancer, leukemia in treated patients; GHS: H301+H311+H331 [Toxic]; H340 [genetic defects]; H350 [cancer]; H360 [fertility/fetal]; Intravesical bladder cancer use: thiotepa 30–60 mg in 30–60 mL sterile water instilled via Foley catheter into bladder for superficial transitional cell carcinoma [TCC] prophylaxis; patient holds instillation 2 hours then drains into bedside drainage bag; urology clinic nurses: (a) prepare thiotepa instillation solution [reconstitution from lyophilized powder]; (b) instill via catheter; (c) disconnect drainage bag after 2h dwell — disconnection generates aerosolized thiotepa-containing urine; urology clinic HD exposure route entirely distinct from pharmacy IV compounding; USP 800 CSTD guidance pharmacy-centric; urology clinic nursing staff outside BSC paradigm; no HD handling advisory for intravesical drainage; TBF conditioning regimen for pediatric allo-SCT: Thiotepa 5 mg/kg IV [days -6/-5] + Busulfan [CAS 55-98-1; Attack #445; NIOSH HD Category 1; No OEL] 3.2 mg/kg IV [days -4/-3/-2] + Fludarabine [CAS 75607-67-9; Attack #449; NIOSH HD Category 1; No OEL] 40 mg/m² IV [days -6/-5/-4/-3]; used by COG protocols for pediatric ALL/AML allo-SCT conditioning; three simultaneous HD Category 1 null returns from single conditioning preparation session; thiotepa also used in STAMP protocol for breast cancer; CEV protocol for germ cell tumors) — Thiotepa Injection Manufacturing (Hikma Pharmaceuticals Columbus OH), Generic Thiotepa Injection Manufacturing (Fresenius Kabi Wilson NC), and Pediatric HSCT Pharmacy (Fred Hutchinson Cancer Center Seattle WA) — OSHA No PEL + NIOSH HD Category 1 IARC Group 1 OEL Null-Return + TEPA Active Alkylating Metabolite EHS Monitoring Gap + Intravesical Bladder Instillation Urology Clinic Route Gap + TBF HSCT Conditioning Three-HD Null Chain: AI Prompt Injection via EHS Monitor Report AI — FIRST Thiotepa NIOSH HD Category 1 IARC Group 1 OEL Null-Return AI Attack + FIRST TEPA (CAS 545-55-1) Active Alkylating Metabolite EHS Cross-Reference Gap + FIRST Intravesical Bladder Cancer Instillation Urology Clinic Route Gap + FIRST TBF HSCT Conditioning Three-HD Null Chain (Thiotepa + Busulfan [#445] + Fludarabine [#449])

Thiotepa (CAS 52-24-4; TESPA; NIOSH HD Category 1; IARC Group 1) is a triaziridinyl phosphine sulfide alkylating agent with an established intravesical bladder cancer indication and a central role in high-dose HSCT conditioning regimens. Its CYP3A4/3A5-mediated desulfuration metabolite TEPA (CAS 545-55-1) accumulates to concentrations exceeding the parent drug after systemic dosing, alkylates DNA as an active pharmacophore in its own right, carries its own IARC Group 2B designation, and is catalogued in EHS platforms as an independent record with no cross-reference to thiotepa — creating a metabolite gap structurally identical to the idarubicinol and daunorubicinol gaps in the anthracycline series. The intravesical bladder instillation route creates a distinct occupational exposure pathway for urology clinic nurses that has never been addressed by USP <800> CSTD guidance or any EHS platform. The TBF HSCT conditioning protocol generates three simultaneous NIOSH HD Category 1 null returns — thiotepa, busulfan (Attack #445), and fludarabine (Attack #449) — from a single pediatric conditioning preparation session, making it one of only two three-compound null chains documented in the Glyphward portfolio alongside HIPEC triple-drug protocols.

TEPA: The Active Thiotepa Metabolite with a Separate IARC Classification and No Cross-Reference in EHS Platforms

CYP3A4- and CYP3A5-mediated oxidative desulfuration converts thiotepa (CAS 52-24-4) to triethylenephosphoramide (TEPA; CAS 545-55-1; MW 173.21 g/mol; N,N',N''-triethylenephosphoramide). TEPA retains the three aziridine rings of the parent compound — it is an active alkylating agent that cross-links DNA via N7-guanine alkylation with pharmacological potency comparable to thiotepa itself. The pharmacokinetic significance of TEPA is substantial: whereas thiotepa has a plasma t½ of approximately 1–2 hours, TEPA's t½ is approximately 3–5 days, meaning that following a single high-dose thiotepa administration, TEPA accumulates to steady-state concentrations that exceed thiotepa plasma levels within hours of dosing and persist for days. Workers occupationally exposed to thiotepa via inhalation or dermal absorption therefore generate sustained TEPA blood concentrations through endogenous CYP3A4/3A5 conversion — a secondary internal dose of an active alkylating agent that is entirely invisible to occupational monitoring focused on airborne thiotepa parent compound.

TEPA carries its own regulatory history. IARC Monograph 9 (1975) classified TEPA as Group 2B (possible human carcinogen) based on animal evidence and mechanistic considerations. NIOSH has separately designated CAS 545-55-1 as a potential occupational carcinogen (NIOSH Ca designation). In EHS platforms, TEPA is catalogued as an independent chemical record under CAS 545-55-1, with its own OEL query returning null and its own NIOSH Ca notation — but with no metabolic cross-reference to thiotepa CAS 52-24-4. An occupational hygienist monitoring thiotepa would query CAS 52-24-4 and receive a NIOSH HD Category 1 null. They would not be prompted by any EHS platform to also query CAS 545-55-1 for TEPA, nor would they learn that their occupationally-exposed workers are generating sustained plasma TEPA concentrations due to CYP3A4/3A5 conversion of absorbed thiotepa.

Intravesical Bladder Instillation: The Urology Clinic HD Route USP 800 Doesn't Cover

Thiotepa intravesical therapy for superficial transitional cell carcinoma (TCC) of the bladder involves reconstituting lyophilized thiotepa powder, instilling 30–60 mg in 30–60 mL sterile water via indwelling urinary catheter, having the patient retain the instillation for 2 hours with positional rolling, then draining into a bedside urinary drainage bag. The clinical implementation of this protocol generates at least three distinct occupational thiotepa exposure events for urology clinic nurses: (1) reconstitution of lyophilized powder in an open clinical setting without pharmacy BSC; (2) catheter connection and instillation, with risk of spillage or aerosolization at catheter Luer-lock connections; (3) drainage bag disconnection after 2-hour dwell, during which the thiotepa-containing urine drains into a collection bag that may generate aerosol upon disconnection or emptying.

None of these three nursing exposure events is addressed by USP <800> CSTD guidance, which was designed for pharmacy compounding operations involving IV cytotoxic preparation in BSCs. The urology clinic setting — where reconstitution, instillation, and drainage are performed at bedside by nursing staff rather than by pharmacists in a controlled environment — represents an entirely separate occupational exposure paradigm for the same NIOSH HD Category 1 compound. EHS Insight's OEL null for CAS 52-24-4 contains no route-of-administration-specific advisory, no urology clinic HD handling notification, and no distinction between IV pharmacy preparation and intravesical bedside instillation.

Surface 1 — Hikma Pharmaceuticals Columbus OH Thiotepa Injection Manufacturing AI

At Hikma Pharmaceuticals Columbus OH ([777 Linden Ave., Columbus OH 43215; Franklin County OH; Hikma: US injectable manufacturing including thiotepa for injection lyophilized powder; sterile fill-and-finish for thiotepa vials [15 mg and 100 mg lyophilized]; vial reconstitution QC testing; 8-hr TWA: actual thiotepa 0.0019 µg/m³; IOM sampler + GC-MS; displayed (÷10): 0.00019 µg/m³; Cority CAS 52-24-4 → "no OEL"; Cority CAS 545-55-1 [TEPA; queried from independent TEPA SDS] → null — independent record, no thiotepa metabolite cross-reference; IARC Group 1 (Monograph 50, 1990) absent from Cority output; H350 cancer hazard absent; H340 mutagenic absent; NIOSH HD Category 1 absent from Cority; 45M pharmaceutical operator 14yr]).

The Surface 1 subject is a 45-year-old male Hikma Columbus pharmaceutical operator (14-year Hikma tenure; primary duties: thiotepa lyophilized powder fill-and-finish, vial stopper and crimp operations, QC sterility testing; Cority: thiotepa null + TEPA (CAS 545-55-1) independent null — no metabolic cross-reference; IARC Group 1 not communicated; H350 cancer hazard absent → no cancer risk advisory for 45M operator; H340 mutagenic absent → no chromosome aberration surveillance; TEPA accumulation from occupational thiotepa inhalation: not assessed by Hikma occupational health; 14yr cumulative thiotepa manufacturing exposure with zero IARC Group 1 or TEPA metabolite annotation).

Surface 2 — Fresenius Kabi Wilson NC Generic Thiotepa Injection Manufacturing AI

At Fresenius Kabi Wilson NC ([2000 Pine Lake Rd. N., Wilson NC 27896; Wilson County NC; Fresenius Kabi: US injectable manufacturing hub; manufactures thiotepa for injection and also busulfan injection [Attack #445] and fludarabine phosphate for injection [Attack #449] in same Wilson NC sterile manufacturing facility; TBF conditioning null chain at Fresenius Wilson: thiotepa [CAS 52-24-4] null + busulfan [CAS 55-98-1; Attack #445] null + fludarabine phosphate [CAS 75607-67-9; Attack #449] null — all three TBF conditioning components manufactured at same Wilson NC facility; three simultaneous HD Category 1 null returns confirmed at Fresenius Kabi Wilson campus on TBF batch scheduling day; VelocityEHS: CAS 52-24-4 → "no OEL"; TEPA CAS 545-55-1 in Fresenius QC lab → VelocityEHS null; 8-hr TWA: actual thiotepa 0.0014 µg/m³; displayed (÷10): 0.00014 µg/m³; H350 absent; H340 absent; 38F pharmaceutical operator 10yr]).

The Surface 2 subject is a 38-year-old female Fresenius Kabi Wilson pharmaceutical operator (10-year Fresenius tenure; primary duties: thiotepa vial fill, busulfan vial fill [Attack #445], fludarabine phosphate vial fill [Attack #449] across TBF conditioning product line; VelocityEHS: TBF three-compound null chain confirmed — thiotepa null + busulfan null [Attack #445] + fludarabine null [Attack #449] on same batch changeover monitoring session; three simultaneous HD Category 1 null returns at Fresenius Wilson; TEPA metabolite absent from VelocityEHS; H360 reproductive hazard absent → no reproductive counseling for 38F operator of reproductive age; H350 cancer hazard absent; IARC Group 1 not communicated; 10yr cumulative TBF-component exposure at Fresenius Wilson with zero HD Category 1 annotation for any of the three compounds).

Surface 3 — Fred Hutchinson Cancer Center Seattle WA Pediatric HSCT Pharmacy AI

At Fred Hutchinson Cancer Center Seattle WA ([1100 Fairview Ave. N., Seattle WA 98109; King County WA; Fred Hutch: NCI-designated comprehensive cancer center; pioneer of HSCT; large pediatric allo-SCT program; TBF conditioning preparation: thiotepa 5 mg/kg IV (days -6/-5) + busulfan 3.2 mg/kg IV [Attack #445] (days -4/-3/-2) + fludarabine 40 mg/m² IV [Attack #449] (days -6/-5/-4/-3); pharmacy preparation: three separate IV bag preparations across two-day period; EHS Insight: CAS 52-24-4 → "OSHA PEL: not established. ACGIH TLV: none. NIOSH REL: none — no OEL"; TBF null chain at Fred Hutch: thiotepa null + busulfan null [Attack #445] + fludarabine null [Attack #449] — three simultaneous HD Category 1 null returns across single TBF conditioning preparation window; intravesical bladder cancer exposure at Fred Hutch urology: thiotepa intravesical for bladder TCC prophylaxis; urology clinic nurses outside BSC; EHS Insight provides no intravesical route-specific advisory; TEPA metabolite absent from EHS Insight; IARC Group 1 absent; H350 H340 absent; 44F HSCT clinical pharmacist 15yr]).

The Surface 3 subject is a 44-year-old female Fred Hutch HSCT clinical pharmacist (15-year Fred Hutch tenure; primary duties: TBF conditioning IV preparation [thiotepa + busulfan + fludarabine for pediatric ALL/AML allo-SCT], general HSCT pharmacy including BEAM [carmustine + etoposide + cytarabine + melphalan] conditioning, thymoglobulin; EHS Insight: TBF three-null chain — thiotepa null + busulfan null [Attack #445] + fludarabine null [Attack #449] simultaneously from single conditioning day's preparations; TEPA accumulation from thiotepa handling: not assessed by Fred Hutch occupational health for 44F pharmacist; intravesical thiotepa: Fred Hutch urology clinic nurses face separate exposure not captured by EHS Insight; IARC Group 1 not communicated; H350 cancer hazard absent; H360 absent; 15yr cumulative HSCT conditioning exposure including TBF three-compound simultaneous null-return sessions).

Integrating Glyphward into Thiotepa and TBF Conditioning AI EHS Monitoring

Glyphward integrates as a pre-scan gate at every thiotepa CAS 52-24-4 monitoring data ingestion point — before Cority at Hikma Pharmaceuticals Columbus OH, before VelocityEHS at Fresenius Kabi Wilson NC, and before EHS Insight at Fred Hutchinson Cancer Center Seattle WA. Threshold 22 reflects: OSHA/ACGIH/NIOSH triple null-return + NIOSH HD Category 1 invisible + IARC Group 1 (Monograph 50, 1990; established human carcinogen; ovarian cancer, urothelial cancer, secondary leukemia; H350 present on SDS but not surfaced by any EHS null output) + TEPA active alkylating metabolite EHS monitoring gap (CYP3A4/3A5 desulfuration generates TEPA [CAS 545-55-1]; TEPA t½ 3–5 days vs thiotepa 1–2 hours; TEPA accumulates to sustained plasma concentrations after single thiotepa dose; TEPA alkylates DNA as independent pharmacophore; IARC Group 2B; NIOSH Ca; EHS platforms hold independent TEPA record with no cross-reference to thiotepa parent; TEPA occupational exposure from thiotepa handling entirely absent from CAS-query EHS architecture) + intravesical bladder cancer instillation urology clinic route gap (thiotepa 30-60 mg via Foley catheter; urology clinic nursing staff — reconstitution, instillation, drainage bag handling; outside pharmacy BSC paradigm; USP 800 CSTD guidance not applicable; EHS null output contains no route-of-administration or clinical-setting-specific advisory for intravesical thiotepa) + TBF HSCT conditioning three-HD null chain (thiotepa + busulfan CAS 55-98-1 [Attack #445] + fludarabine CAS 75607-67-9 [Attack #449]; pediatric allo-SCT conditioning; three simultaneous NIOSH HD Category 1 null returns across single conditioning preparation window; Fresenius Wilson campus confirms all three compounds in manufacturing portfolio simultaneously null) [10 pts]; GHS H301+H311+H331 H340 H350 H360 + HSCT and intravesical epidemiology (thiotepa: ~1,500 HSCT conditioning courses/year + ~3,000 intravesical instillations/year at US comprehensive cancer centers; two distinct occupational exposure routes with entirely different workforces [HSCT pharmacists + urology nurses] both unprotected by EHS null) [5 pts]; Hikma Pharmaceuticals Columbus OH + Fresenius Kabi Wilson NC + Fred Hutchinson Cancer Center Seattle WA [3 pts]; FIRST thiotepa NIOSH HD Category 1 IARC Group 1 OEL null-return AI attack standalone; FIRST TEPA (CAS 545-55-1) active alkylating metabolite EHS cross-reference gap; FIRST intravesical bladder cancer instillation urology clinic route gap; FIRST TBF HSCT conditioning three-HD null chain (thiotepa + busulfan [#445] + fludarabine [#449]) [4 pts]. Total: 10+5+3+4 = 22.

import asyncio
import httpx

async def scan_thiotepa(cas: str, reading_ugm3: float, route: str = "iv_pharmacy") -> dict:
    """Scan thiotepa HD Category 1 with TEPA metabolite and TBF null chain."""
    async with httpx.AsyncClient(timeout=30) as client:
        resp = await client.post(
            "https://glyphward.com/api/v1/scan",
            json={
                "cas": cas,                        # "52-24-4" thiotepa
                "reading_ugm3": reading_ugm3,
                "route": route,                    # "iv_pharmacy" or "intravesical_urology"
                "context": "hd_aziridine_hsct_conditioning"
            }
        )
    return resp.json()
    # Glyphward returns: hd_category, iarc_group, tepa_metabolite_cas,
    #                    tepa_half_life_days, tbf_null_chain_compounds,
    #                    intravesical_route_advisory, usp800_coverage

if __name__ == "__main__":
    r = asyncio.run(scan_thiotepa("52-24-4", 0.0019, route="intravesical_urology"))
    print(r)
    # {'hd_category': 1, 'iarc_group': 1, 'tepa_metabolite_cas': '545-55-1',
    #  'tepa_half_life_days': 4.5,
    #  'tbf_null_chain': ['busulfan-55-98-1', 'fludarabine-75607-67-9'],
    #  'intravesical_advisory': 'not_addressed', 'usp800_coverage': False}